Dassault Systèmes SE

Total revenue reached EUR 1.552 billion, up 5% year over year. Subscription revenue grew 6%, licenses grew 14%, and service revenue grew 7%. Operating margin was 31.6%, up 150 basis points year over year ex-FX, and operating profit rose 10%. EPS was EUR 0.32, up 8% ex-FX. Year to date, revenue was EUR 4.617 billion, up 4%; operating margin was 30.6%, up 80 bps; and EPS was EUR 0.93, up 7% ex-FX. ARR was EUR 4.505 billion, up 6%, and cash conversion was 111% year to date. For Q4, management expects revenue growth of 5% to 8% including a 2-point contribution from ArisGlobal, operating margin of 37.2% to 37.8%, and EPS of EUR 0.42 to EUR 0.43. For the full year, revenue growth is guided to 4% to 5% on a EUR 6.399 billion to EUR 6.459 billion range, operating margin to 32.5% to 32.7%, and EPS growth to 6% to 7% or EUR 1.35 to EUR 1.36.

Pascal Daloz framed 2026 as a foundational year focused on building an AI-native platform, expanding 3DEXPERIENCE into an agent platform, and connecting virtual twins to real-world industrial outcomes. He emphasized three priorities: helping existing customers transform, integrating ArisGlobal to strengthen Life Sciences, and scaling 3D UNIV+RSES and AI use cases. His tone was constructive and confident, repeatedly stressing that the company is delivering now while preparing for the next wave of growth.

Rouven Bergmann highlighted that execution improved through the year, with revenue growth moving from 3% in Q1 to 4% in Q2 and 5% in Q3. He pointed to 150 bps of operating margin expansion to 31.6%, cash conversion of 111% YTD, operating cash flow of EUR 1.567 billion, and free cash flow of EUR 1.388 billion YTD. He also noted cash and cash equivalents of EUR 3.814 billion at end-September, net cash of EUR 1.049 billion, and that YTD operating cash flow funded the EUR 1.5 billion ArisGlobal acquisition and the repayment of a EUR 0.9 billion bond. On guidance, he narrowed the revenue range and raised margin and EPS targets, citing better visibility and year-to-date outperformance.

Analysts focused on the remaining execution priorities, Americas phasing, the apparent Q4 organic growth deceleration, contract liabilities, and the relationship between ARR and subscription revenue. Daloz said the main execution items are Life Sciences integration and scaling, rebuilding the partner ecosystem for CP partners, and scaling AI adoption in 2027; he also said there is still room to improve organizational agility and that some functions could be consolidated, especially in Life Sciences. Bergmann said the Americas weakness was mainly a tough comparison and that Q4 transactions are well identified, while he explained that the ARR/subscription bridge is affected by comparisons and by upfront recognition on some on-premise deals; he said contract liabilities simply reflect stronger business activity and cash collections, not a problem.